Detalhe da pesquisa
1.
Direct enhancement of viral neutralising antibody potency by the complement system: a largely forgotten phenomenon.
Cell Mol Life Sci
; 81(1): 22, 2024 Jan 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-38200235
2.
Complement-Mediated Neutralisation Identified in Ebola Virus Disease Survivor Plasma: Implications for Protection and Pathogenesis.
Front Immunol
; 13: 857481, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35493467
3.
Divergent trajectories of antiviral memory after SARS-CoV-2 infection.
Nat Commun
; 13(1): 1251, 2022 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35273178
4.
Filovirus Neutralising Antibodies: Mechanisms of Action and Therapeutic Application.
Pathogens
; 10(9)2021 Sep 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-34578233
5.
Longitudinal antibody and T cell responses in Ebola virus disease survivors and contacts: an observational cohort study.
Lancet Infect Dis
; 21(4): 507-516, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33065039
6.
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Nat Med
; 27(2): 279-288, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33335322
7.
Viral Evasion of the Complement System and Its Importance for Vaccines and Therapeutics.
Front Immunol
; 11: 1450, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-32733480
8.
Ebolavirus: Comparison of Survivor Immunology and Animal Models in the Search for a Correlate of Protection.
Front Immunol
; 11: 599568, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33679690
9.
Oropouche virus cases identified in Ecuador using an optimised qRT-PCR informed by metagenomic sequencing.
PLoS Negl Trop Dis
; 14(1): e0007897, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31961856
10.
Detection of Crimean-Congo Haemorrhagic Fever cases in a severe undifferentiated febrile illness outbreak in the Federal Republic of Sudan: A retrospective epidemiological and diagnostic cohort study.
PLoS Negl Trop Dis
; 13(7): e0007571, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31291242
11.
Author Correction: Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses.
Nat Med
; 27(6): 1113, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33958800